Author:
He Tingshan,Li Hong,Zhang Zhiqiao
Abstract
Abstract
Purpose
The current study aimed to explore the prognosis of ovarian cancer patients in different subgroup using three prognostic research indexes. The current study aimed to build a prognostic model for ovarian cancer patients.
Methods
The study dataset was downloaded from Surveillance Epidemiology and End Results database. Accelerated Failure Time algorithm was used to construct a prognostic model for ovary cancer.
Results
The mortality rate in the model group was 51.6% (9,314/18,056), while the mortality rate in the validation group was 52.1% (6,358/12,199). The current study constructed a prognostic model for ovarian cancer patients. The C indexes were 0.741 (95% confidence interval: 0.731–0.751) in model dataset and 0.738 (95% confidence interval: 0.726–0.750) in validation dataset. Brier score was 0.179 for model dataset and validation dataset. The C indexes were 0.741 (95% confidence interval: 0.733–0.749) in bootstrap internal validation dataset. Brier score was 0.178 for bootstrap internal validation dataset.
Conclusion
The current research indicated that there were significant differences in the survival benefits of treatments among ovarian cancer patients with different stages. The current research developed an individual mortality risk predictive system that could provide valuable predictive information for ovarian cancer patients.
Graphical Abstract
Publisher
Springer Science and Business Media LLC
Subject
Obstetrics and Gynecology,Oncology
Reference33 articles.
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
2. Wu SG, Li FY, Lei J, Hua L, He ZY, Zhou J. Histological tumor type is associated with one-year cause-specific survival in women with stage III-IV epithelial ovarian cancer: a Surveillance, Epidemiology, and End Results (SEER) database population study, 2004–2014. Med Sci Monit. 2020;26: e920531.
3. Karimi-Zarchi M, Mortazavizadeh SM, Bashardust N, Zakerian N, Zaidabadi M, Yazdian-Anari P, Teimoori S. The clinicopathologic characteristics and 5-year survival rate of epithelial ovarian cancer in Yazd. Iran Electron Physician. 2015;7(6):1399–406.
4. Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, DeSimone CP, Ueland FR, van Nagell JR, Seamon LG. Ten-year relative survival for epithelial ovarian cancer. Obstetr Gynecol. 2012;120(3):612–8.
5. Kunito S, Takakura S, Nagata C, Saito M, Yanaihara N, Yamada K, Okamoto A, Sasaki H, Ochiai K, Tanaka T. Long-term survival in patients with clear cell adenocarcinoma of ovary treated with irinotecan hydrochloride plus cisplatin therapy as first-line chemotherapy. J Obstetr Gynaecol Res. 2012;38(12):1367–75.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献